{"database":"iProX","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Yubo Zhou"],"species":["Homo Sapiens"],"full_dataset_link":["http://www.iprox.org/page/project.html?id=IPX0018186000"],"submitter_email":["ybzhou@simm.ac.cn"],"submitter_affiliation":["Zhongshan Institute  for Drug Discovery"],"sample_protocol":[""],"repository":["iProX"],"data_protocol":[""],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Selective and Potent BRPF1 Dege-reraders for the Treatment of Endocrine-sensitive Breast Cancer","description":"ESR1 mutations and activation of growth factor signaling (e.g., PI3K-AKT) drive endocrine therapy resistance in breast cancer, largely limiting the success of breast cancer treatment. We reported a first-in-class, selective and potent BRPF1-targeted proteolysis-targeting chimera (PROTAC) B-8, and it downregulated H3K23ac and ER, causing cell cycle arrest and autophagic cell death.","dates":{"publication":"Mon Jul 06 00:00:00 GMT+01:00 2026"},"accession":"PXD080650","cross_references":{"TAXONOMY":["9606"]}}